Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Sex: Male

Ages: 18 Years – 100 Years

Phase: PHASE2

Enrollment: 40

Sponsor: University Health Network, Toronto

Summary

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Eligibility Criteria

Inclusion Criteria:Histologically-proven metastatic prostate cancerPresence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)Receiving systemic treatment ADT +/- ARAT (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)Planned for EBRTECOG 0 or 1Age 18 years or olderExclusion Criteria:Prior radiotherapy to pelvisActive ulcerative colitis or Crohn's Disease, at discretion of treating physicianAny condition where radiotherapy is contraindicated

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05656794). StuddyBuddy aggregates publicly available trial information.